HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TTS Pharma’s CBD Animal Studies Show Anti-Inflammatory Potential

Executive Summary

Can cannabinoids provide therapeutic benefits to consumers? A new animal study by the UK's TTS Pharma suggests anti-inflammatory properties for CBD, according to the company's director of Medical Affairs, Rob Walton.

You may also be interested in...

Hiding In Plain Sight: Can TTS Pharma’s ‘Assured Advice’ Unlock UK’s CBD Mass Market?

UK CBD supplier TTS Pharma believes its strategy of establishing partnerhips with local food law enforcement agencies as part of the "assured advice" scheme will unlock the country's cautious mass market. However, without proactive enforcement, the company worries that the UK food authority's legislative efforts to remove sub-standard CBD products from the market, as well as TTS' own efforts to become compliant, will be in vain. 

TTS Pharma Wants To Bring First Legal CBD Oil To The UK

TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.

Patience Wins The Race: TTS Pharma's CEO On Bringing The First Legal CBD Oil To The UK Market

TTS Pharma wants to be the first to launch a legal CBD oil onto the UK wellness market. TTS CEO Mark Tucker explains how his firm's CBD is produced according to strict standards and can provide a model for future regulation. 


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts